|
CENTRAL
AMERICA |
Hard to Treat Diseases (HTDS)
Acquired Varicella Approval in Guatemala
Hard to Treat Diseases and its subsidiary
Mellow Hope announce that the company
received Registration Certificate for its
MEVAC-Vari vaccine in Guatemala.
This is the first Final Approval for HTDS'
Varicella vaccine in South America.
In general, doctors regard Varicella,
commonly known as chickenpox, as a mild
viral illness. However, approximately 1 in
50 cases chickenpox associates with
complications such as pneumonia and
encephalitis, and both diseases report high
mortality rate.
A source close to HTDS said, "Varicella
complications can be averted by a simple
vaccination, and we are happy that we
obtained the Registration Certificate for
our Freeze-dried Varicella vaccine (Mevac-Vari)
in Guatemala."
As it is Mellow Hope's first Final Approval
in South America, they see it as an
important step and a very good start for the
Varicella vaccine on the South American
market. South America offers great potential
for our affordable vaccines.
|
|
|
|
|
|
|
|
